Zymeworks (ZYME) Non Operating Income (2021 - 2026)
Zymeworks recorded quarterly Non Operating Income of $120000.0 in Q1 2026, up 139.74% quarter-over-quarter from -$302000.0 in Q4 2025, and up 144.9% year-over-year from $49000.0 in Q1 2025.
Zymeworks' Non Operating Income history runs 6 years deep, the most recent figure standing at $120000.0 for Q1 2026.
- In Q1 2026, Non Operating Income rose 144.9% year-over-year to $120000.0; the TTM figure through Mar 2026 stood at -$488000.0 (down 261.06% YoY), while the FY2025 annual figure was -$559000.0, down 200.18% from the prior year.
- Non Operating Income came in at $120000.0 for Q1 2026 at Zymeworks, up from -$302000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $1.4 million in Q3 2022 to a low of -$832000.0 in Q4 2023.
- A 5-year average of $19705.9 and a median of $49000.0 in 2025 frame the typical range for Non Operating Income.
- Across the five-year window, Non Operating Income sank 2406.67% in 2022 and surged 254.41% in 2025, its largest moves.
- Zymeworks' Non Operating Income stood at -$692000.0 in 2022, then declined by 20.23% to -$832000.0 in 2023, then soared by 141.35% to $344000.0 in 2024, then sank by 187.79% to -$302000.0 in 2025, then jumped by 139.74% to $120000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $120000.0, -$302000.0, and $315000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | 120,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 120,000.00 |
| Dec 31, 2025 | -302,000.00 |
| Sep 30, 2025 | 315,000.00 |
| Jun 30, 2025 | -621,000.00 |
| Mar 31, 2025 | 49,000.00 |
| Dec 31, 2024 | 344,000.00 |
| Sep 30, 2024 | -204,000.00 |
| Jun 30, 2024 | 114,000.00 |
| Mar 31, 2024 | 304,000.00 |
| Dec 31, 2023 | -832,000.00 |
| Sep 30, 2023 | 634,000.00 |
| Jun 30, 2023 | -209,000.00 |
| Mar 31, 2023 | -487,000.00 |
| Dec 31, 2022 | -692,000.00 |
| Sep 30, 2022 | 1.36 Mn |
| Jun 30, 2022 | 759,000.00 |
| Mar 31, 2022 | -315,000.00 |
| Dec 31, 2021 | 30,000.00 |
| Sep 30, 2021 | 1.15 Mn |